View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

Breast cancer drug rejected despite doubling in tumour destruction

In In The News by Barbara Jacoby

By: Laura Donnelly From: telegraph.co.uk A breast cancer drug that has been shown to almost double the eradication of tumours has been rejected for use on the NHS. In draft guidance, the National Institute for Health and Care Excellence (Nice) said it was uncertain how the effects of Perjeta (also called pertuzumab) seen in clinical trials would translate into long-term …

View Post

Global Non-Hematological Cancers Market Will Almost Double to $141 Billion by 2021

In In The News by Barbara Jacoby

The global treatment market for non-hematological cancers, which includes breast, colorectal, lung and prostate cancers, among others, will almost double from $72.9 billion in 2014 to $140.8 billion in 2021, at a compound annual growth rate (CAGR) of 9.9%, according to business intelligence provider GBI Research. The company’s latest report* states that this robust growth will occur in spite of …

Could This Breast Cancer Vaccine Be a Game Changer?

In In The News by Barbara Jacoby

By Leo Sun Breast cancer claims more than 40,000 lives in the United States annually and is one of the leading causes of death for females globally. However, every year biotech companies are making incredible advances in breast cancer treatments that could eventually eradicate this debilitating disease. A breast cancer vaccine One of the most promising new treatments is Galena Biopharma‘s …

CHMP recommends EU approval of Roche’s Subcutaneous Herceptin for HER2 positive breast cancer

In In The News by Barbara Jacoby

(Menafn – M2 PRESSWIRE via COMTEX) New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients’ time Herceptin is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (six:RO)(six:ROG)(otcqx:RHHBY) is pleased to announce that the …

In Resistant Breast Cancer, Two Antibodies Are Better Than One

In In The News by Barbara Jacoby

Israeli-devised ‘double whammy’ antibody is a promising approach to a deadly aggressive form of breast cancer. By Rivka Borochov Breast cancer is often thought of as a curable disease if caught early. But there is an aggressive type with poor prognosis because existing drugs don’t seem to work. Called triple negative breast cancer, it occurs in about one in six …